NOS2 and prostate cancer: We can hypothesize that when the levels of iNOS are high (as in squamous tumors, and colon and prostate cancer) [62,63], the best approach is to use NOS inhibitors, whereas NO-based derivatives can be proposed for tumors with low/moderate levels of iNOS, thereby promoting a reduction in NO levels and inflammation.